Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$3.33 USD
+0.05 (1.47%)
Updated Oct 18, 2024 03:56 PM ET
After-Market: $3.30 -0.03 (-0.90%) 6:48 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.33 USD
+0.05 (1.47%)
Updated Oct 18, 2024 03:56 PM ET
After-Market: $3.30 -0.03 (-0.90%) 6:48 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acasti Pharma (ACST) and Cigna (CI) have performed compared to their sector so far this year.
TEVA Q3 Earnings In Line, Sales Beat, Revenue View Raised
by Zacks Equity Research
TEVA reports decent third-quarter results. The company raises its revenue guidance for 2023 for the second time this year while keeping the EPS range intact.
TEVA to Pay $225 Million to Settle Price-Fixing Charges (Revised)
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
TEVA to Pay $250 Million to Settle Price-Fixing Charges
by Zacks Equity Research
TEVA agrees to pay a fine of $225 million over five years per a DPA. Out of this amount, $22.5 million will be due each year from 2024 through 2027 and $135 million will become due in 2028.
Here's Why You Should Add Dr. Reddy's (RDY) to Your Portfolio
by Zacks Equity Research
Dr. Reddy's (RDY) continues to enjoy a strong foothold in the global generics market due to its deep generic drugs pipeline. The company is also looking to strengthen its biosimilars portfolio.
TEVA Q2 Earnings & Sales Top as Austedo Outperforms, Stock Up
by Zacks Equity Research
TEVA's second-quarter results were strong as it beat estimates for earnings as well sales.
Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Dr. Reddy's (RDY) reports better-than-expected fiscal first-quarter 2024 results.
Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Acasti Pharma (ACST) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
TEVA Shares Rise on Broad Support for Opioids Settlement
by Zacks Equity Research
With the required participation from states and local governments, TEVA can now move forward with the nationwide settlement.
New Strong Sell Stocks for February 23rd
by Zacks Equity Research
ARR, ACST, and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on February 23, 2022
Acasti (ACST) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zynerba Pharmaceuticals (ZYNE) Jumps: Stock Rises 7.7%
by Zacks Equity Research
Zynerba Pharmaceuticals (ZYNE) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
What Makes Acasti (ACST) a New Buy Stock
by Zacks Equity Research
Acasti (ACST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Uncertainty Looms Large Over Generic Drug Industry Players
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs lead to recovery in the industry. New launches also provide a boost. However, coronavirus crisis creates an uncertainty for the industry.
FDA Advisory Committee Recommends Mallinckrodt's Trelipressin
by Zacks Equity Research
The Cardiovascular and Renal Drugs Advisory Committee of the FDA votes in favor of Mallinckrodt's (MNK) investigational agent, terlipressin, to treat adults with hepatorenal syndrome type 1.
FDA Advisory Committee to Review Mallinckrodt'sTerlipressin
by Zacks Equity Research
Mallinckrodt (MNK) announces that the Cardiovascular and Renal Drugs Advisory Committee of the FDA will hold a virtual meeting to review data on terlipressin.
AstraZeneca to End Phase III Study on Fish Oil Heart Drug
by Zacks Equity Research
AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee
Amarin's Shares Down on Underperform Rating by Oppenheimer
by Zacks Equity Research
Amarin's (AMRN) shares decline as the independent advisory firm, Oppenheimer, initiates coverage with an Underperform rating on the back of concerns related to its marketed drug, Vascepa.
Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
by Zacks Equity Research
Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.
Price Stabilization Leads to Generic Drugs Industry's Recovery
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs is leading to a recovery in revenues of industry participants. New launches are also providing a boost. However, competition remains stiff.
Generic Industry on Path to Recovery: 3 Hot Picks for 2019
by Zacks Equity Research
The stability in the industry sets the stage for players to get back on growth track. Here we discuss three stocks picks from the industry.